Immune Cell-Targeting Biologics for Alopecia Areata: A New Paradigm in Precision Medicine

The review article explores the use of immune cell-targeting biologics for treating alopecia areata (AA), an autoimmune disorder that leads to hair loss. It assesses several biologics, such as rituximab, abatacept, alefacept, efalizumab, nivolumab, and aldesleukin. Rituximab and nivolumab resulted in complete hair regrowth in isolated cases, although these findings are anecdotal. Abatacept showed partial regrowth in some patients, while alefacept, efalizumab, and aldesleukin were mostly ineffective in controlled trials, despite some individual successes. Biologics targeting B and T cells demonstrated moderate efficacy, indicating potential as AA treatments, but more effective targets are needed. Adverse events were mild, with no serious incidents reported.